S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73% Market Closed
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Other Current Assets
ÂĄ32.1m
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Current Assets
ÂĄ1.1B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Current Assets
ÂĄ552.8m
CAGR 3-Years
-5%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Current Assets
ÂĄ74.5m
CAGR 3-Years
18%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Current Assets
ÂĄ93.1m
CAGR 3-Years
-22%
CAGR 5-Years
17%
CAGR 10-Years
22%
Imeik Technology Development Co Ltd
SZSE:300896
Other Current Assets
ÂĄ33.5m
CAGR 3-Years
74%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Other Current Assets?
Other Current Assets
32.1m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Other Current Assets amounts to 32.1m CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
35%

Over the last year, the Other Current Assets growth was -35%. The average annual Other Current Assets growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 35% over the past three years .

Back to Top